Education, Science, Technology, Innovation and Life
Open Access
Sign In

Exploration on the Mechanism of Cryptotanshinone in Treating Kashin-beck Disease Based on Network Pharmacology

Download as PDF

DOI: 10.23977/medbm.2024.020102 | Downloads: 12 | Views: 216

Author(s)

Qinfeng Zhang 1, Weizhuo Wang 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Department of Orthopedics Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shaanxi, 710004, China

Corresponding Author

Weizhuo Wang

ABSTRACT

In order to explore the possible mechanism of cryptotanshinone (CTS) in the treatment of Kashin-beck disease (KBD) based on network pharmacology, we obtained CTS drug targets from TCMSP, CTD and DGIdb databases, and we searched Genecard, TTD, OMIM and Dragbank databases with "KBD" as the keyword to obtain the disease target of KBD. Drug-disease gene interaction was performed in Venny2.1.0 to obtain the intersection target. String database and Cytoscape 3.7.1 were used for protein-protein interaction network (PPI) analysis, and DAVID database was used for GO enrichment and KEGG enrichment pathway analysis. The "drug-target-pathway-disease" network diagram was constructed by Cytoscape. Resultly, a total of 10 key targets were selected, 125 items in 3 directions were obtained by GO enrichment analysis, and 34 signaling pathways were obtained by KEGG enrichment analysis. In conclusion, through network pharmacological analysis, CTS can treat KBD through multi-target and multi-pathway. 

KEYWORDS

Cryptotanshinone; Kashin-beck disease; Network pharmacology

CITE THIS PAPER

Qinfeng Zhang, Weizhuo Wang, Exploration on the Mechanism of Cryptotanshinone in Treating Kashin-beck Disease Based on Network Pharmacology. MEDS Basic Medicine (2024) Vol. 2: 8-14. DOI: http://dx.doi.org/10.23977/medbm.2024.020102.

REFERENCES

[1] Wang Kewei, Yu Jun, Liu Hui, et al. Endemic Kashin–Beck disease: A food-sourced osteoarthropathy [J]. Seminars in Arthritis and Rheumatism, 2020, 50(2):366-372. 
[2] Yu Fangfang, Zuo Juan, Sun Lei, et al. Animal models of Kashin-Beck disease exposed to environmental risk factors: Methods and comparisons [J]. Ecotoxicology and Environmental Safety, 2022, 234:113419-113419. 
[3] Fu Guotao, Chen Xueqin, Qi Meng, et al. Status and potential diagnostic roles of essential trace elements in Kashin- Beck disease patients [J]. Journal of Trace Elements in Medicine and Biology, 2022, 69:126880-126880. 
[4] Ye Zhiqiang, et al. Expanding the therapeutic potential of Salvia miltiorrhiza: a review of its pharmacological applications in musculoskeletal diseases [J]. Frontiers in Pharmacology, 2023, 14:1276038-1276038. 
[5] Feng Jinghui, Jung Jeon Sub, Hwang Seung Hwan, et al. The mixture of;Agrimonia pilosa;Ledeb. and ;Salvia miltiorrhiza;Bunge. extract produces analgesic and anti-inflammatory effects in a collagen-induced arthritis mouse model [J]. Animal Cells and Systems, 2022, 26(4):166-173. 
[6] He Jianbo, Li Xiaojuan, Wang Ziyi, et al. Therapeutic Anabolic and Anticatabolic Benefits of Natural Chinese Medicines for the Treatment of Osteoporosis [J]. Frontiers in pharmacology, 2019, 10:1344. 
[7] B. Bai, Y. Li. Danshen prevents articular cartilage degeneration via antioxidation in rabbits with osteoarthritis [J]. Osteoarthritis and Cartilage, 2016, 24(3):514-520. 
[8] Zhenhua Feng, Wenhao Zheng, Xiaobin Li, et al. Cryptotanshinone protects against IL-1β-induced inflammation in human osteoarthritis chondrocytes and ameliorates the progression of osteoarthritis in mice [J]. International Immunopharmacology, 2017, 50:161-167. 
[9] Luo Tingting, Lu Yuan, Yan Shikai, et al. Network Pharmacology in Research of Chinese Medicine Formula: Methodology, Application and Prospective [J]. Chinese journal of integrative medicine, 2020, 26(1):72-80. 
[10] Nie Hong, Zheng Yingxia, Li Runsheng, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis [J]. Nature medicine, 2013, 19(3):322-328. 
[11] Wang Tiantian, He Chengqi. Pro-inflammatory cytokines: the link between obesity and osteoarthritis [J]. Cytokine and Growth Factor Reviews, 2018, 44:38-50. 
[12] Arden Nigel K., Perry Thomas A., Bannuru Raveendhara R., et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines [J]. Nature Reviews Rheumatology, 2020, 17(1):59-66. 
[13] Roel Nusse, Hans Clevers. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities [J]. Cell, 2017, 169(6):985-999. 
[14] Sharma Leena. Osteoarthritis of the Knee [J]. New England Journal of Medicine, 2021, 384(1):51-59. 
[15] Huang Rongxiang, Hui Zhang, Wei Sun, et al. IRE1 signaling regulates chondrocyte apoptosis and death fate in the osteoarthritis [J]. Journal of cellular physiology, 2021, 237(1):118-127. 
[16] Wang Cuicui, Shen Jie, Ying Jun, et al. FoxO1 is a crucial mediator of TGF-β/TAK1 signaling and protects against osteoarthritis by maintaining articular cartilage homeostasis [J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(48):30488-30497. 
[17] Consuelo Ibar, Kenneth D. Irvine. Integration of Hippo-YAP Signaling with Metabolism [J]. Developmental Cell, 2020, 54(2):256-267. 
[18] AbouJaoude A, Courtes M, Badique L, et al. ShcA promotes chondrocyte hypertrophic commitment and osteoarthritis in mice through RunX2 nuclear translocation and YAP1 inactivation [J]. Osteoarthritis and cartilage, 2022, 30(10):1365-1375. 
[19] Zhang Zhongyin, Yuan Lichan, Liu Yufeng, et al. Integrated cascade nanozyme remodels chondrocyte inflammatory microenvironment in temporomandibular joint osteoarthritis via inhibiting ROS-NF-κB and MAPK pathways [J]. Advanced healthcare materials, 2023, 12(10):e2203195-e2203195. 
[20] Lu Jiansen, Zhang Hongbo, Pan Jianying, et al. Fargesin ameliorates osteoarthritis via macrophage reprogramming by downregulating MAPK and NF-κB pathways [J]. Arthritis research & therapy, 2021, 23(1):142-142. 
[21] Wang Xiaolin, Guo Zhou, Lin Jiamin, et al. Indirubin protects chondrocytes and alleviates OA by inhibiting the MAPK and NF-κB pathways [J]. International immunopharmacology, 2022, 115:109624-109624.

Downloads: 432
Visits: 13601

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.